$RVNC
Revance Therapeutics, Inc. Stock $rvnc

$rvnc Overview Financials Valuation SEC Filings Company Website

2022 Q2 Form 10-Q Financial Statement

#000119312522146362 Filed on May 10, 2022

Income Statement

Concept	2022 Q2	2022 Q1	2021 Q4
Revenue	$28.37M	$25.26M	$25.95M
YoY Change	50.86%	89.95%	133.15%
Cost Of Revenue	$9.523M	$7.893M	$7.881M
YoY Change	75.51%	87.04%	115.33%
Gross Profit	$18.85M	$17.37M	$18.07M
YoY Change	40.87%	91.28%	141.89%
Gross Profit Margin	66.43%	68.75%	69.63%
Selling, General & Admin	$46.19M	$45.08M	$44.56M
YoY Change	-8.72%	-8.02%	-14.11%
% of Gross Profit	245.08%	259.53%	246.62%
Research & Development	$24.91M	$30.73M	$29.47M
YoY Change	-15.38%	12.76%	0.78%
% of Gross Profit	132.2%	176.93%	163.09%
Depreciation & Amortization	$5.451M	$5.376M	$5.419M
YoY Change	8.07%	26.76%	25.44%
% of Gross Profit	28.93%	30.95%	29.99%
Operating Expenses	$76.69M	$75.80M	$79.67M
YoY Change	-4.19%	-0.59%	-6.75%
Operating Profit	-$57.84M	-$62.22M	-$61.60M
YoY Change	-17.76%	-11.13%	-20.99%
Interest Expense	-$3.316M	$1.931M	-$1.343M
YoY Change	-311.34%	23.78%	-53.21%
% of Operating Profit
Other Income/Expense, Net	-$277.0K	-$222.0K	-$151.0K
YoY Change	-22.41%	111.43%	-20.53%
Pretax Income	-$61.44M	-$64.34M	-$63.10M
YoY Change	-14.91%	-10.19%	-22.13%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$61.44M	-$64.30M	-$63.10M
YoY Change	-14.91%	-10.24%	-19.43%
Net Earnings / Revenue	-216.56%	-254.54%	-243.15%
Basic Earnings Per Share	-$0.88	-$0.94
Diluted Earnings Per Share	-$876.9K	-$0.94	-$926.0K
COMMON SHARES
Basic Shares Outstanding	72.77M shares	68.33M shares	71.79M shares
Diluted Shares Outstanding	70.06M shares	68.33M shares

Balance Sheet

Concept	2022 Q2	2022 Q1	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$233.8M	$262.6M	$225.1M
YoY Change	-30.47%	-32.11%	-48.44%
Cash & Equivalents	$69.42M	$198.4M	$110.6M
Short-Term Investments	$164.4M	$64.23M	$114.4M
Other Short-Term Assets	$7.940M	$7.612M	$7.544M
YoY Change	-36.99%	-13.5%	30.07%
Inventory	$13.60M	$10.70M	$10.20M
Prepaid Expenses
Receivables	$5.590M	$4.471M	$3.348M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$260.9M	$285.3M	$246.1M
YoY Change	-26.41%	-29.8%	-45.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$81.80M	$23.50M	$24.66M
YoY Change	287.8%	13.15%	40.93%
Goodwill		$147.0M	$147.0M
YoY Change		0.0%	0.0%
Intangibles			$55.33M
YoY Change			-22.44%
Long-Term Investments
YoY Change
Other Assets	$25.16M	$13.33M	$8.701M
YoY Change	426.96%	670.68%	552.25%
Total Long-Term Assets	$300.9M	$354.2M	$285.0M
YoY Change	5.12%	31.42%	5.49%
TOTAL ASSETS
Total Short-Term Assets	$260.9M	$285.3M	$246.1M
Total Long-Term Assets	$300.9M	$354.2M	$285.0M
Total Assets	$561.9M	$639.5M	$531.2M
YoY Change	-12.33%	-5.39%	-26.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$13.27M	$10.02M	$10.60M
YoY Change	62.33%	41.55%	-16.23%
Accrued Expenses	$31.26M	$25.32M	$39.56M
YoY Change	-0.48%	-6.59%	20.1%
Deferred Revenue		$8.980M	$9.362M
YoY Change		-0.73%	19.25%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$17.72M	$18.87M
YoY Change
Total Short-Term Liabilities	$77.23M	$71.07M	$67.29M
YoY Change	32.58%	39.79%	10.37%
LONG-TERM LIABILITIES
Long-Term Debt	$378.4M	$430.9M	$280.6M
YoY Change	35.14%	54.05%	55.48%
Other Long-Term Liabilities	$108.9M	$2.504M	$1.485M
YoY Change	-6.43%	-97.53%
Total Long-Term Liabilities	$487.3M	$2.504M	$1.485M
YoY Change	22.93%	-99.34%
TOTAL LIABILITIES
Total Short-Term Liabilities	$77.23M	$71.07M	$67.29M
Total Long-Term Liabilities	$487.3M	$2.504M	$1.485M
Total Liabilities	$564.5M	$614.0M	$462.7M
YoY Change	24.17%	42.23%	33.75%
SHAREHOLDERS EQUITY
Retained Earnings		-$1.500B	-$1.398B
YoY Change		25.0%	24.12%
Common Stock		$1.488B	$1.466B
YoY Change		3.86%	-2.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.631M	$25.54M	$68.47M
YoY Change
Total Liabilities & Shareholders Equity	$561.9M	$639.5M	$531.2M
YoY Change	-12.33%	-5.39%	-26.25%

Cashflow Statement

Concept	2022 Q2	2022 Q1	2021 Q4
OPERATING ACTIVITIES
Net Income	-$61.44M	-$64.30M	-$63.10M
YoY Change	-14.91%	-10.24%	-19.43%
Depreciation, Depletion And Amortization	$5.451M	$5.376M	$5.419M
YoY Change	8.07%	26.76%	25.44%
Cash From Operating Activities	-$44.23M	-$61.27M	-$44.61M
YoY Change	-9.74%	-18.04%	-28.4%
INVESTING ACTIVITIES
Capital Expenditures	$536.0K	$1.456M	-$4.357M
YoY Change	-154.92%	-63.92%	97.15%
Acquisitions
YoY Change
Other Investing Activities	-$106.4M	$46.02M	$32.00M
YoY Change	206.53%	-233.87%	-593.8%
Cash From Investing Activities	-$105.9M	$44.57M	$27.64M
YoY Change	196.64%	-216.0%	-418.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$8.997M
YoY Change		-58.55%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	21.16M	$105.3M	405.0K
YoY Change	625.82%	262.6%	-99.4%
NET CHANGE
Cash From Operating Activities	-44.23M	-$61.27M	-44.61M
Cash From Investing Activities	-105.9M	$44.57M	27.64M
Cash From Financing Activities	21.16M	$105.3M	405.0K
Net Change In Cash	-128.9M	$88.61M	-16.57M
YoY Change	57.67%	-205.33%	350.14%
FREE CASH FLOW
Cash From Operating Activities	-$44.23M	-$61.27M	-$44.61M
Capital Expenditures	$536.0K	$1.456M	-$4.357M
Free Cash Flow	-$44.76M	-$62.73M	-$40.25M
YoY Change	-6.79%	-20.39%	-33.02%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001479290
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2021	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member
CY2021	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member
CY2021Q2	rvnc	Collaborative Agreement Extended Contractual Period CollaborativeAgreementExtendedContractualPeriod	P1Y
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-36297
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	Revance Therapeutics, Inc.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0551645
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1222 Demonbreun Street, Suite 2000
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Nashville
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	TN
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	37203
CY2022Q1	dei	City Area Code CityAreaCode	615
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	724-7755
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022Q1	dei	Trading Symbol TradingSymbol	RVNC
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	72768161	shares
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	198359000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	110623000	USD
CY2022Q1	us-gaap	Short Term Investments ShortTermInvestments	64231000	USD
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	114448000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4471000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3348000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	10657000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	10154000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7612000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7544000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	285330000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	246117000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	23496000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24661000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	146964000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	146964000	USD
CY2022Q1	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	51178000	USD
CY2021Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	55334000	USD
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	70280000	USD
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	0	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	43052000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	44340000	USD
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	5921000	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	5046000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13325000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8701000	USD
CY2022Q1	us-gaap	Assets Assets	639546000	USD
CY2021Q4	us-gaap	Assets Assets	531163000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	10020000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10603000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	25315000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	39558000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	8980000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	9362000	USD
CY2022Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	18874000	USD
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4813000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4746000	USD
CY2022Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	3064000	USD
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	3020000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	71066000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	67289000	USD
CY2022Q1	us-gaap	Long Term Debt LongTermDebt	377951000	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	280635000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	71650000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	74152000	USD
CY2022Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	52914000	USD
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	37920000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	39131000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2504000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1485000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	614005000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	462692000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	190000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	190000000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71763765	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	71763765	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	71584057	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71584057	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	72000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	72000	USD
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1487822000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1466369000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-59000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-18000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1462294000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1397952000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	25541000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	68471000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	639546000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	531163000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25261000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13299000	USD
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	45075000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	49005000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30729000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27251000	USD
CY2022Q1	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	3785000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	2838000	USD
CY2022Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	87482000	USD
CY2021Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	83311000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-62221000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-70012000	USD
CY2022Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	76000	USD
CY2021Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	97000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	1931000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	1560000	USD
CY2022Q1	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-44000	USD
CY2021Q1	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-59000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-222000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-105000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-64342000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-71639000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-41000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-64383000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-71639000	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-64342000	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-64342000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-71639000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-71639000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.94
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.94
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.08
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.08
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	68333117	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	68333117	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	66636830	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	66636830	shares
CY2022Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	USD
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	71763765	shares
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	25541000	USD
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	71411389	shares
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	244247000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-64342000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-71639000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	14363000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	10607000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5376000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4241000	USD
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	343000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	310000	USD
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-78000	USD
CY2021Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	55000	USD
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-158000	USD
CY2021Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-59000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1123000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3357000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	503000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-247000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-209000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3006000	USD
CY2022Q1	rvnc	Increase Decreasein Operating Lease Rightof Use Assets IncreaseDecreaseinOperatingLeaseRightofUseAssets	68992000	USD
CY2021Q1	rvnc	Increase Decreasein Operating Lease Rightof Use Assets IncreaseDecreaseinOperatingLeaseRightofUseAssets	-853000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	115000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	395000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-930000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4996000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-14571000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-5582000	USD
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities in the condensed </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated financial statements and accompanying notes. These estimates form the basis for judgments we make about the carrying values of our assets and liabilities, which are not readily apparent from other sources. We base our estimates and judgments on historical information and on various other assumptions that we believe are reasonable under the circumstances. U.S. GAAP requires us to make estimates and judgments in several areas, including, but not limited to, the incremental borrowing rate used to measure operating lease and finance lease liabilities, the recoverability of goodwill and long-lived assets, useful lives associated with property and equipment and intangible assets, the period of benefit associated with deferred costs, revenue recognition (including the timing of satisfaction of performance obligations, estimating variable consideration, estimating stand-alone selling prices of promised goods and services, and allocation of transaction price to performance obligations), deferred revenue classification, accruals for clinical trial costs, valuation and assumptions underlying stock-based compensation and other equity instruments, the fair value of derivative liability, and income taxes.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full extent of the impact of the COVID-19 pandemic on our future operational and financial performance will depend on future developments that are highly uncertain, including variant strains of the virus and the degree of their vaccine resistance and as a result of new information that may emerge concerning COVID-19, the actions taken to contain or treat it, and the duration and intensity of the related effects. The ongoing COVID-19 pandemic has and may continue to negatively affect global economic activity, the regulatory approval process for our product candidates, our supply chain, research and development activities, end user demand for our products and services and commercialization activities. The COVID-19 pandemic has caused delays in the regulatory approval process for DaxibotulinumtoxinA for Injection. In November 2020, the FDA deferred a decision on the BLA for DaxibotulinumtoxinA for Injection for the treatment of glabellar lines. The FDA reiterated that an inspection of our manufacturing facility was required as part of the BLA approval process, but the FDA was unable to conduct the required inspection due to the FDA’s travel restrictions associated with the COVID-19 pandemic. Although the inspection has been completed, in October 2021, we received a CRL due to deficiencies related to the FDA’s onsite inspection at our manufacturing facility. We resubmitted the BLA in March 2022, and in April 2022, the FDA accepted the resubmission of the BLA and designated the BLA as a Class 2 resubmission with a Prescription Drug User Fee Act (“PDUFA”) date of September 8, 2022, with a reinspection required. We cannot be certain of the continued impact of the COVID-19 pandemic on the regulatory approval process for the BLA for DaxibotulinumtoxinA for Injection for the treatment of glabellar lines, including the timing of the FDA's reinspection of the manufacturing facility, whether the PDUFA date will be met or the future impact of the COVID-19 pandemic on the timing of the regulatory approval process for DaxibotulinumtoxinA for Injection in indications outside of glabellar lines or on any supplemental BLAs we may file.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of issuance of these condensed consolidated financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, judgments or revise the carrying value of our assets or liabilities. These estimates may change as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to our condensed consolidated financial statements.</span></div>
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2884000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1132000	USD
CY2022Q1	rvnc	Increase Decreasein Operating Lease Liabilities IncreaseDecreaseinOperatingLeaseLiabilities	70644000	USD
CY2021Q1	rvnc	Increase Decreasein Operating Lease Liabilities IncreaseDecreaseinOperatingLeaseLiabilities	-910000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	1019000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-61270000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-74755000	USD
CY2022Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	72000000	USD
CY2021Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	53000000	USD
CY2022Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	22016000	USD
CY2021Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	87384000	USD
CY2022Q1	rvnc	Prepayments For A Finance Lease PrepaymentsForAFinanceLease	3960000	USD
CY2021Q1	rvnc	Prepayments For A Finance Lease PrepaymentsForAFinanceLease	0	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1456000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4036000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	44568000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-38420000	USD
CY2022Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	98150000	USD
CY2021Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8997000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	21706000	USD
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	79000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	11136000	USD
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2377000	USD
CY2021Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3645000	USD
CY2022Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	464000	USD
CY2021Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2021Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	153000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	105313000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	29044000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	88611000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-84131000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115669000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	337003000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	204280000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	252872000	USD
CY2022Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	1716000	USD
CY2021Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-64300000	USD
CY2022Q1	rvnc	Working Capital Surplus WorkingCapitalSurplus	214300000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1500000000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	100000000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	262600000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25261000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13299000	USD
CY2022Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	31000000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	71650000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	74152000	USD
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	82079000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	3568000	USD
CY2022Q1	rvnc	Contract With Customer Liability Billings And Adjustments Net ContractWithCustomerLiabilityBillingsAndAdjustmentsNet	884000	USD
CY2022Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	79395000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	230875000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	59000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	230816000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	204821000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	18000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	204803000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	230816000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	204803000	USD
CY2021	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2022Q1	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2022Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	78434000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	27256000	USD
CY2022Q1	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	51178000	USD
CY2021Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	78434000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	23100000	USD
CY2021Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	55334000	USD
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4157000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3506000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	12469000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	16625000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	10837000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	5967000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	4606000	USD
CY2022Q1	rvnc	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	674000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	51178000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	10700000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	10200000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11678000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	22761000	USD
CY2022Q1	rvnc	Selling General And Administrative Accrued SellingGeneralAndAdministrativeAccrued	4825000	USD
CY2021Q4	rvnc	Selling General And Administrative Accrued SellingGeneralAndAdministrativeAccrued	5688000	USD
CY2022Q1	rvnc	Research And Development Accrual ResearchAndDevelopmentAccrual	4549000	USD
CY2021Q4	rvnc	Research And Development Accrual ResearchAndDevelopmentAccrual	5152000	USD
CY2022Q1	rvnc	Accruals Clinical Trials Current AccrualsClinicalTrialsCurrent	2030000	USD
CY2021Q4	rvnc	Accruals Clinical Trials Current AccrualsClinicalTrialsCurrent	2172000	USD
CY2022Q1	us-gaap	Interest Payable Current InterestPayableCurrent	609000	USD
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1887000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	843000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1442000	USD
CY2022Q1	rvnc	Accrued Inventory Current AccruedInventoryCurrent	781000	USD
CY2021Q4	rvnc	Accrued Inventory Current AccruedInventoryCurrent	456000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	25315000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	39558000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	48045000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	47990000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	24549000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	23329000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	23496000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24661000	USD
CY2022Q1	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	30000000	USD
CY2022Q1	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	30000000	USD
CY2022Q1	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	30000000	USD
CY2022Q1	rvnc	Purchase Obligation Term Of Written Notice PurchaseObligationTermOfWrittenNotice	P18M
CY2022Q1	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	30000000	USD
CY2022Q1	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	30000000	USD
CY2022Q1	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	30000000	USD
CY2022Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	1508000	USD
CY2021Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	0	USD
CY2022Q1	rvnc	Finance Lease Variable Cost FinanceLeaseVariableCost	1390000	USD
CY2021Q1	rvnc	Finance Lease Variable Cost FinanceLeaseVariableCost	0	USD
CY2022Q1	rvnc	Total Finance Lease Costs TotalFinanceLeaseCosts	2898000	USD
CY2021Q1	rvnc	Total Finance Lease Costs TotalFinanceLeaseCosts	0	USD
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	2223000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1704000	USD
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	434000	USD
CY2021Q1	us-gaap	Variable Lease Cost VariableLeaseCost	283000	USD
CY2022Q1	rvnc	Total Operating Lease Costs TotalOperatingLeaseCosts	2657000	USD
CY2021Q1	rvnc	Total Operating Lease Costs TotalOperatingLeaseCosts	1987000	USD
CY2022Q1	us-gaap	Lease Cost LeaseCost	5555000	USD
CY2021Q1	us-gaap	Lease Cost LeaseCost	1987000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	14489000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	6244000	USD
CY2022Q1	rvnc	Lease Liability To Be Payment Remainder Of Fiscal Year LeaseLiabilityToBePaymentRemainderOfFiscalYear	20733000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	34875000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	8468000	USD
CY2022Q1	rvnc	Lease Liability To Be Payment Due Year One LeaseLiabilityToBePaymentDueYearOne	43343000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	26898000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	8723000	USD
CY2022Q1	rvnc	Lease Liability To Be Payment Due Year Two LeaseLiabilityToBePaymentDueYearTwo	35621000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	4875000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	8981000	USD
CY2022Q1	rvnc	Lease Liability To Be Payment Due Year Three LeaseLiabilityToBePaymentDueYearThree	13856000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	9242000	USD
CY2022Q1	rvnc	Lease Liability To Be Payment Due Year Four LeaseLiabilityToBePaymentDueYearFour	9242000	USD
CY2022Q1	rvnc	Finance Lease Liability To Be Paid Due After Year Four FinanceLeaseLiabilityToBePaidDueAfterYearFour	0	USD
CY2022Q1	rvnc	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	17146000	USD
CY2022Q1	rvnc	Lease Liability Payments Due After Year Four LeaseLiabilityPaymentsDueAfterYearFour	17146000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	81137000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	58804000	USD
CY2022Q1	rvnc	Lease Liability To Be Payment Due LeaseLiabilityToBePaymentDue	139941000	USD
CY2022Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	9349000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	16071000	USD
CY2022Q1	rvnc	Lease Liability Undiscounted Excess Amount LeaseLiabilityUndiscountedExcessAmount	25420000	USD
CY2022Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	71788000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	42733000	USD
CY2022Q1	rvnc	Lease Liability LeaseLiability	114521000	USD
CY2022Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y2M12D
CY2022Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.085
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.098
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	2076000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1761000	USD
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	70280000	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	USD
CY2022Q1	us-gaap	Other Commitment Due In Next Twelve Months OtherCommitmentDueInNextTwelveMonths	16000000	USD
CY2022Q1	us-gaap	Other Commitment Due In Second Year OtherCommitmentDueInSecondYear	13000000	USD
CY2022Q1	us-gaap	Other Commitment Due In Third Year OtherCommitmentDueInThirdYear	18000000	USD
CY2022Q1	us-gaap	Other Commitment Due In Fourth Year OtherCommitmentDueInFourthYear	25000000	USD
CY2022Q1	us-gaap	Other Commitment Due In Fifth Year OtherCommitmentDueInFifthYear	30000000	USD
CY2022Q1	us-gaap	Other Commitment Due After Fifth Year OtherCommitmentDueAfterFifthYear	135000000	USD
CY2022Q1	us-gaap	Long Term Debt LongTermDebt	377951000	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	280635000	USD
CY2022Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	1588000	USD
CY2021Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	1258000	USD
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	332000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	310000	USD
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	11000	USD
CY2021Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2022Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	1931000	USD
CY2021Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	1568000	USD
CY2020Q1	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	28900000	USD
CY2020Q1	rvnc	Capped Calls Price Cap CappedCallsPriceCap	48.88
CY2020Q1	rvnc	Capped Calls Premium Percentage Over Sale Price CappedCallsPremiumPercentageOverSalePrice	1
CY2020Q1	rvnc	Capped Calls Number Of Shares Subject To Anti Dilution Adjustments CappedCallsNumberOfSharesSubjectToAntiDilutionAdjustments	8900000	shares
CY2020Q1	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	28900000	USD
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14363000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10607000	USD
CY2022Q1	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	272400000	USD
CY2022Q1	rvnc	Indemnification Liability Recorded During Period IndemnificationLiabilityRecordedDuringPeriod	0	USD
CY2021Q1	rvnc	Indemnification Liability Recorded During Period IndemnificationLiabilityRecordedDuringPeriod	0	USD
CY2021Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	257100000	USD
CY2022Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2022Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25261000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13299000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-62221000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-70012000	USD

Files In Submission

Name	View Source	Status
0001193125-22-146362-index-headers.html	Edgar Link	pending
0001193125-22-146362-index.html	Edgar Link	pending
0001193125-22-146362.txt	Edgar Link	pending
0001193125-22-146362-xbrl.zip	Edgar Link	pending
d327432d10q.htm	Edgar Link	pending
d327432d10q_htm.xml	Edgar Link	completed
d327432dex102.htm	Edgar Link	pending
d327432dex103.htm	Edgar Link	pending
d327432dex104.htm	Edgar Link	pending
d327432dex311.htm	Edgar Link	pending
d327432dex312.htm	Edgar Link	pending
d327432dex321.htm	Edgar Link	pending
d327432dex322.htm	Edgar Link	pending
d327432dex51.htm	Edgar Link	pending
d327432dex991.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g327432g0510060627871.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rvnc-20220331.xsd	Edgar Link	pending
rvnc-20220331_cal.xml	Edgar Link	unprocessable
rvnc-20220331_def.xml	Edgar Link	unprocessable
rvnc-20220331_lab.xml	Edgar Link	unprocessable
rvnc-20220331_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RVNC
Revance Therapeutics, Inc. Stock $rvnc

2022 Q2 Form 10-Q Financial Statement

#000119312522146362 Filed on May 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC Revance Therapeutics, Inc. Stock $rvnc

2022 Q2 Form 10-Q Financial Statement

#000119312522146362 Filed on May 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC
Revance Therapeutics, Inc. Stock $rvnc